Please try another search
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Name | Age | Since | Title |
---|---|---|---|
Eric E. Poma | 49 | 2009 | CEO, Chief Scientific Officer & Director |
Harold E. Selick | 67 | 2017 | Independent Chairman |
Kevin M. Lalande | 51 | 2017 | Independent Director |
Burkhard Jansen | 57 | - | Member of Scientific Advisory Board |
Neil L. Berinstein | - | - | Member of Scientific Advisory Board |
Michel Klein | 85 | - | Member of Scientific Advisory Board |
David R. Hoffmann | 78 | 2017 | Independent Director |
Corazon Dating Sanders | 67 | 2019 | Independent Director |
Gabriela Gruia | 68 | 2022 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review